GB8608335D0 - Pharmaceutically acceptable salts - Google Patents

Pharmaceutically acceptable salts

Info

Publication number
GB8608335D0
GB8608335D0 GB868608335A GB8608335A GB8608335D0 GB 8608335 D0 GB8608335 D0 GB 8608335D0 GB 868608335 A GB868608335 A GB 868608335A GB 8608335 A GB8608335 A GB 8608335A GB 8608335 D0 GB8608335 D0 GB 8608335D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutically acceptable
acceptable salts
salts
pharmaceutically
acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB868608335A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Original Assignee
PFIZER Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB8608335(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PFIZER Ltd filed Critical PFIZER Ltd
Priority to GB868608335A priority Critical patent/GB8608335D0/en
Publication of GB8608335D0 publication Critical patent/GB8608335D0/en
Priority to LU86812A priority patent/LU86812A1/fr
Priority to CN87102493A priority patent/CN1023800C/zh
Priority to DE19873710457 priority patent/DE3710457A1/de
Priority to EG191/87A priority patent/EG18266A/xx
Priority to ES87302767T priority patent/ES2012803B3/es
Priority to GB8707653A priority patent/GB2188630B/en
Priority to EP87302767A priority patent/EP0244944B1/en
Priority to SE8701348A priority patent/SE463457B/sv
Priority to DE8787302767T priority patent/DE3761485D1/de
Priority to AT87302767T priority patent/ATE49752T1/de
Priority to MX584787A priority patent/MX5847A/es
Priority to MYPI87000413A priority patent/MY101177A/en
Priority to PH35098A priority patent/PH24348A/en
Priority to GR870525A priority patent/GR870525B/el
Priority to CA000533732A priority patent/CA1321393C/en
Priority to YU580/87A priority patent/YU44801B/xx
Priority to IN281/DEL/87A priority patent/IN168414B/en
Priority to AR87307197A priority patent/AR242562A1/es
Priority to PT84611A priority patent/PT84611B/pt
Priority to CS872363A priority patent/CS265237B2/cs
Priority to APAP/P/1987/000060A priority patent/AP50A/en
Priority to SI8710580A priority patent/SI8710580A8/sl
Priority to IL82101A priority patent/IL82101A/xx
Priority to FR8704705A priority patent/FR2596758B1/fr
Priority to DD87301485A priority patent/DD265142A5/de
Priority to UA4202353A priority patent/UA6344A1/uk
Priority to HU871450A priority patent/HU196962B/hu
Priority to FI871470A priority patent/FI85017C/fi
Priority to ES8700965A priority patent/ES2002599A6/es
Priority to AU71030/87A priority patent/AU573123C/en
Priority to IE86987A priority patent/IE59457B1/en
Priority to NZ219868A priority patent/NZ219868A/xx
Priority to MA21175A priority patent/MA20938A1/fr
Priority to BE8700349A priority patent/BE1000130A4/fr
Priority to DK170187A priority patent/DK171708B1/da
Priority to NO871408A priority patent/NO172181C/no
Priority to NL8700791A priority patent/NL8700791A/nl
Priority to PL1987264982A priority patent/PL149532B1/pl
Priority to JP62082787A priority patent/JPS62240660A/ja
Priority to ZA872439A priority patent/ZA872439B/xx
Priority to IT19977/87A priority patent/IT1203853B/it
Priority to SU874202353A priority patent/SU1498388A3/ru
Priority to KR1019870003209A priority patent/KR950006710B1/ko
Priority to US07/256,938 priority patent/US4879303A/en
Priority to GR90400158T priority patent/GR3000394T3/el
Priority to SK3539-91A priority patent/SK278435B6/sk
Priority to CS19913539A priority patent/CZ289095B6/cs
Priority to BG096073A priority patent/BG60698B2/xx
Priority to SG596/92A priority patent/SG59692G/en
Priority to HK760/92A priority patent/HK76092A/en
Priority to CY1669A priority patent/CY1669A/xx
Priority to LV931082A priority patent/LV5619A3/xx
Priority to EC1994001129A priority patent/ECSP941129A/es
Priority to LV950056A priority patent/LV5716B4/xx
Priority to HR950452A priority patent/HRP950452B1/xx
Priority to BA970148A priority patent/BA97148B1/bs
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
GB868608335A 1986-04-04 1986-04-04 Pharmaceutically acceptable salts Pending GB8608335D0 (en)

Priority Applications (57)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts
LU86812A LU86812A1 (fr) 1986-04-04 1987-03-18 Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant
CN87102493A CN1023800C (zh) 1986-04-04 1987-03-30 一种药物组合物的制备方法
DE19873710457 DE3710457A1 (de) 1986-04-04 1987-03-30 Verbesserung bei pharmazeutisch verwendbaren salzen
EG191/87A EG18266A (en) 1986-04-04 1987-03-31 Improvements in pharmaceutically acceptable salts
ES87302767T ES2012803B3 (es) 1986-04-04 1987-03-31 Sales de amlodipina.
GB8707653A GB2188630B (en) 1986-04-04 1987-03-31 Improvements in pharmaceutically acceptable salts
EP87302767A EP0244944B1 (en) 1986-04-04 1987-03-31 Salts of amlodipine
SE8701348A SE463457B (sv) 1986-04-04 1987-03-31 Bensensulfonatsaltet av amlodipin, farmaceutiska beredningsformer daerav och anvaendning av saltet foer behandling av hjaertsjukdom eller hypertension
DE8787302767T DE3761485D1 (de) 1986-04-04 1987-03-31 Amlodipin-salze.
AT87302767T ATE49752T1 (de) 1986-04-04 1987-03-31 Amlodipin-salze.
MX584787A MX5847A (es) 1986-04-04 1987-04-01 La sal de besilato de amlodipina y procedimiento para su preparacion
MYPI87000413A MY101177A (en) 1986-04-04 1987-04-01 Improvements in pharmaceutically acceptable salts
PH35098A PH24348A (en) 1986-04-04 1987-04-02 Improvements in pharmaceutically acceptable salts of amlodipine
GR870525A GR870525B (en) 1986-04-04 1987-04-02 Improvements in pharmaceutically acceptable salts
CA000533732A CA1321393C (en) 1986-04-04 1987-04-02 Besylate salt of amlodipine
YU580/87A YU44801B (en) 1986-04-04 1987-04-02 Process for obtaining benzolsulphonate salt of 3-ethyl-5-methyl-2-(2-aminoetoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl pyridin-3,5-dicarboxylate
IN281/DEL/87A IN168414B (enExample) 1986-04-04 1987-04-02
AR87307197A AR242562A1 (es) 1986-04-04 1987-04-02 Un procedimiento para preparar la sal besilato de amlodipina.
PT84611A PT84611B (pt) 1986-04-04 1987-04-02 Processo para a preparacao de benzenossulfonato de 2-(2-aminoetoximetil)-4-(2-clorofenil)-1,4-di-hidro-6-metilpiridino-3,5-dicarboxilato 3-etilico 5-metilico
CS872363A CS265237B2 (en) 1986-04-04 1987-04-02 Process for preparing salt of 3-ethyl-5-methyl-2-/aminoethoxymethyl/4-/2-chlorphenyl/-1,4-dihydro-6-methylpyridin-3,5-dicarboxylate with benzensulphonic acid
APAP/P/1987/000060A AP50A (en) 1986-04-04 1987-04-02 Improvements in pharmaceutially acceptable salts.
SI8710580A SI8710580A8 (sl) 1986-04-04 1987-04-02 Postopek za pridobivanje benzolsulfonatne soli 3-etil-5-metil-2-(2-aminoetoksimetil)- 4-{2-klorofenil)-1.4-dihidro-6- metilpiridin-3.5-dikarboksilata
IL82101A IL82101A (en) 1986-04-04 1987-04-03 Amlodipine besylate and pharmaceutical compositions containing it
FR8704705A FR2596758B1 (fr) 1986-04-04 1987-04-03 Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant
DD87301485A DD265142A5 (de) 1986-04-04 1987-04-03 Verfahren zur herstellung des besylatsalzes von amlodipin
UA4202353A UA6344A1 (uk) 1986-04-04 1987-04-03 Спосіб одержання бензолсульфонатної солі 3-етіл-5метілового ефіру 2-(2-аміноетоксіметіл)-4-(2-хлорфеніл)-6-метіл-1,4-дігідропірідін-3,5-дікарбонової кислоти
HU871450A HU196962B (en) 1986-04-04 1987-04-03 Process for producing amlodipin-bezilate
FI871470A FI85017C (fi) 1986-04-04 1987-04-03 Foerfarande foer framstaellning av terapeutiskt anvaendbart besylatsalt av amlodipin.
ES8700965A ES2002599A6 (es) 1986-04-04 1987-04-03 Un procedimiento para la preparacion de la sal de besilato de amlodipina
AU71030/87A AU573123C (en) 1986-04-04 1987-04-03 Amlodipine benzene sulphonate and pharmaceutical compositions thereof
IE86987A IE59457B1 (en) 1986-04-04 1987-04-03 Salts of amlodipine
NZ219868A NZ219868A (en) 1986-04-04 1987-04-03 Amlodipine salts (3 ethyl 5-methyl -2-(aminoethoxymethyl)- 4-(2-chlorophenyl)-1,4-dihydro-6-methylpyridine-3,5- dicarboxylate) and pharmaceutical compositions
MA21175A MA20938A1 (fr) 1986-04-04 1987-04-03 Procede de preparation du besylate d'amlodipine.
BE8700349A BE1000130A4 (fr) 1986-04-04 1987-04-03 Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant.
DK170187A DK171708B1 (da) 1986-04-04 1987-04-03 Benzensulfonatsaltet af amlodipin og farmaceutiske præparater indeholdende dette
NO871408A NO172181C (no) 1986-04-04 1987-04-03 Fremgangsmaate ved fremstilling av et terapeutisk aktivt benzensulfonatsalt av amlodipin
NL8700791A NL8700791A (nl) 1986-04-04 1987-04-03 Amlodipine-zout en preparaat dat dat bevat.
PL1987264982A PL149532B1 (en) 1986-04-04 1987-04-03 Method of obtaining pharmaceutically acceptable amidipine salt
JP62082787A JPS62240660A (ja) 1986-04-04 1987-04-03 アムロジピンのベンゼンスルホン酸塩
ZA872439A ZA872439B (en) 1986-04-04 1987-04-03 Pharmaceutically acceptable salts
IT19977/87A IT1203853B (it) 1986-04-04 1987-04-03 Sali di amlodipina farmaceuticamente accettabili, migliorati
SU874202353A SU1498388A3 (ru) 1986-04-04 1987-04-03 Способ получени бензолсульфонатной соли 3-этил-5-метилового эфира 2- (2-аминоэтоксиметил )-4-(2-хлорфенил)-6-метил-1,4-дигидропиридин-3,5-дикарбоновой кислоты
KR1019870003209A KR950006710B1 (ko) 1986-04-04 1987-04-04 암로디핀의 베실레이트염의 제조방법
US07/256,938 US4879303A (en) 1986-04-04 1988-10-13 Pharmaceutically acceptable salts
GR90400158T GR3000394T3 (en) 1986-04-04 1990-03-21 Salts of amlodipine
SK3539-91A SK278435B6 (en) 1986-04-04 1991-11-22 Amlodipine benzylate salt and pharmaceutical composition containing its
CS19913539A CZ289095B6 (cs) 1986-04-04 1991-11-22 Besylátová sůl amlodipinu a farmaceutický prostředek
BG096073A BG60698B2 (en) 1986-04-04 1992-03-16 Pharmaceutical ACCEPTABLE SALTS
SG596/92A SG59692G (en) 1986-04-04 1992-06-04 Salts of amlodipine
HK760/92A HK76092A (en) 1986-04-04 1992-10-01 Salts of amlodipine
CY1669A CY1669A (en) 1986-04-04 1993-05-14 Salts of amlodipine
LV931082A LV5619A3 (lv) 1986-04-04 1993-09-22 Panemiens 2-(2-aminoetoksimetil)-4-(2-hlorfenil)-6-metil-1,4-dihidropiridina-3,5-dikarbonskabes 3-etil-5-metilestera benzolsulfoskabes sais iegusanai
EC1994001129A ECSP941129A (es) 1986-04-04 1994-07-26 Un procedimiento para la preparacion de la sal de besilato de amlodipina
LV950056A LV5716B4 (lv) 1986-04-04 1995-03-15 Farmaceitiski pienemami sali
HR950452A HRP950452B1 (en) 1986-04-04 1995-08-16 Process for the preparation of benzosulphonate salts 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)1,4-dihydro-6-methylpyridine -3,5-dicarboxylate
BA970148A BA97148B1 (bs) 1986-04-04 1997-03-28 Postupak za dobivanje benzolsulfonatne soli 3-etil-5-metil-2-(aminoetoksimetil)-4-(2-klorofenil) 1,4-dihidro-6-metilpiridin-3,5-dikarboksilata

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
GB8608335D0 true GB8608335D0 (en) 1986-05-08

Family

ID=10595731

Family Applications (2)

Application Number Title Priority Date Filing Date
GB868608335A Pending GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts
GB8707653A Expired - Lifetime GB2188630B (en) 1986-04-04 1987-03-31 Improvements in pharmaceutically acceptable salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB8707653A Expired - Lifetime GB2188630B (en) 1986-04-04 1987-03-31 Improvements in pharmaceutically acceptable salts

Country Status (47)

Country Link
US (1) US4879303A (enExample)
EP (1) EP0244944B1 (enExample)
JP (1) JPS62240660A (enExample)
KR (1) KR950006710B1 (enExample)
CN (1) CN1023800C (enExample)
AP (1) AP50A (enExample)
AR (1) AR242562A1 (enExample)
AT (1) ATE49752T1 (enExample)
BE (1) BE1000130A4 (enExample)
BG (1) BG60698B2 (enExample)
CA (1) CA1321393C (enExample)
CS (1) CS265237B2 (enExample)
CY (1) CY1669A (enExample)
CZ (1) CZ289095B6 (enExample)
DD (1) DD265142A5 (enExample)
DE (2) DE3710457A1 (enExample)
DK (1) DK171708B1 (enExample)
EC (1) ECSP941129A (enExample)
EG (1) EG18266A (enExample)
ES (2) ES2012803B3 (enExample)
FI (1) FI85017C (enExample)
FR (1) FR2596758B1 (enExample)
GB (2) GB8608335D0 (enExample)
GR (2) GR870525B (enExample)
HK (1) HK76092A (enExample)
HU (1) HU196962B (enExample)
IE (1) IE59457B1 (enExample)
IL (1) IL82101A (enExample)
IN (1) IN168414B (enExample)
IT (1) IT1203853B (enExample)
LU (1) LU86812A1 (enExample)
MA (1) MA20938A1 (enExample)
MX (1) MX5847A (enExample)
MY (1) MY101177A (enExample)
NL (1) NL8700791A (enExample)
NO (1) NO172181C (enExample)
NZ (1) NZ219868A (enExample)
PH (1) PH24348A (enExample)
PL (1) PL149532B1 (enExample)
PT (1) PT84611B (enExample)
SE (1) SE463457B (enExample)
SG (1) SG59692G (enExample)
SK (1) SK278435B6 (enExample)
SU (1) SU1498388A3 (enExample)
UA (1) UA6344A1 (enExample)
YU (1) YU44801B (enExample)
ZA (1) ZA872439B (enExample)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
JPH07501547A (ja) * 1991-11-26 1995-02-16 セプラコア，インコーポレーテッド 光学的に純粋な（−）アムロジピンを用いる，高血圧，狭心症および他の疾患を治療するための方法および組成物
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ATE235251T1 (de) 1995-03-16 2003-04-15 Pfizer Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
WO1999018957A1 (en) * 1998-03-26 1999-04-22 Reddy-Cheminor, Inc. Stable pharmaceutical composition containing amlodipine besylate and atenolol
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
DK1096932T3 (da) 1998-07-10 2007-10-15 Novartis Pharma Ag Antihypertensiv kombination af valsartan og calciumkanalblokker
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
UA33033A (uk) * 1998-10-16 2001-02-15 Др.Редіс Леборетрис Лтд Спосіб одержання безилату амлодипіну
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
AP2001002345A0 (en) 1999-05-27 2001-12-31 Pfizer Prod Inc Mutual prodrugs of amlodipine and atorvastatin.
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
RU2161156C1 (ru) * 1999-06-01 2000-12-27 Джи.Б.Кемикалс Энд Фармасьютикалс Лтд Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты
UA72768C2 (en) * 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
WO2002011723A1 (en) 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
EP1309556B1 (en) 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
BR0116553A (pt) * 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
EP1309554A1 (en) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Amide derivative of amlodipine
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
GB2371862B (en) 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
ATE300520T1 (de) * 2000-12-29 2005-08-15 Pfizer Ltd Verfahren zur herstellung amlodipinmaleat
CA2433190C (en) 2000-12-29 2005-11-15 Pfizer Limited Amlodipine hemimaleate
EP1221438B1 (de) * 2001-01-09 2007-03-14 Siegfried Generics International AG Salze von Amlodipin-Mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
EP1435954B1 (en) 2001-07-06 2010-01-13 LEK Pharmaceuticals D.D. A PROCESS FOR THE PREPARATION OF HIGHlLY PUREAMLODIPINE BENZENESULFONATE
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
AR037565A1 (es) * 2001-11-21 2004-11-17 Synthon Bv Formas de sales de amlodipina y procedimientos para prepararlas.
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20070135488A1 (en) * 2002-04-13 2007-06-14 Chung You S Amlodipine nicotinate and process for the preparation thereof
CN101648028B (zh) 2002-05-06 2012-11-21 恩多塞特公司 维生素-定向的显象剂
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
RU2221784C1 (ru) * 2002-07-05 2004-01-20 Марвел Лайфсайнсез Прайвит Лимитед Способ получения бензолсульфоната амлодипина
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
CN1310885C (zh) 2002-08-29 2007-04-18 大正制药株式会社 4－氟－2－氰基吡咯烷衍生物苯磺酸盐
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
JP4319148B2 (ja) 2002-09-11 2009-08-26 ハンリム ファーマシューティカル カンパニー リミテッド Ｓ−（−）−アムロジピンニコチネート及びその製造方法
AU2003253460A1 (en) * 2002-09-19 2004-04-08 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
MXPA05007876A (es) 2003-01-27 2005-09-21 Hanmi Pharm Ind Co Ltd Camsilato de amlodipino amorfo, estable, proceso para preparar el mismo y composicion para la administracion oral del mismo.
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
US20060270715A1 (en) * 2003-02-28 2006-11-30 Singh Romi B Dosage forms of amlodipine and processes for their preparation
DE112004000712T5 (de) * 2003-04-25 2006-10-19 Cipla Ltd. Verfahren zur Herstellung von Amlodipinmesilat-Monohydrat
EP2113506A3 (en) 2003-04-25 2010-02-24 Cadila Healthcare Limited Salts of clopidogrel and process for preparation
US20040242673A1 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
BRPI0410840A (pt) 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
RU2239433C1 (ru) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060035940A1 (en) * 2004-03-16 2006-02-16 Sepracor Inc. (S)-Amlodipine malate
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
CN101035541B (zh) * 2004-08-30 2012-05-30 柳署弘 溶解的udca在局灶缺血模型中的神经保护作用
CN101039699B (zh) * 2004-10-15 2011-07-27 柳署弘 用于减小药物化合物毒性的方法和组合物
DE602005025391D1 (de) * 2004-11-01 2011-01-27 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
EP1833466A1 (en) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
CA2610838A1 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
DK1797885T3 (da) * 2005-09-28 2008-07-14 Teva Pharma Stabil kombination af amlodipinbesylat og benazeprilhydrochlorid
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
EP2051735B1 (en) 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
WO2008093984A1 (en) 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
WO2009038396A2 (en) * 2007-09-21 2009-03-26 Hanall Pharmaceutical Company. Ltd N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
MX2010007281A (es) 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
RU2359672C1 (ru) * 2008-02-18 2009-06-27 Зао "Биоком" Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2012505885A (ja) * 2008-10-20 2012-03-08 ゼノポート，インコーポレーテッド レボドパエステルプロドラッグを合成する方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
JPWO2010070705A1 (ja) * 2008-12-17 2012-05-24 株式会社 メドレックス アムロジピンの安定な含水経口製剤
US9161933B2 (en) 2009-01-23 2015-10-20 Hanmi Science Co., Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
WO2011056240A2 (en) * 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CA2782514A1 (en) 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
CA3024216C (en) 2010-02-12 2021-03-30 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
EP2539857A4 (en) 2010-02-24 2013-07-24 Univ Ramot CRYSTALLINE FORMS OF TRI MESYLATE SALT OF PERPHENAZINE GABA AND METHOD OF MANUFACTURING THEREOF
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
NZ607845A (en) * 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
PT2825042T (pt) 2012-03-15 2018-11-16 Celgene Car Llc Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico
MX356753B (es) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014122585A1 (en) 2013-02-08 2014-08-14 Wockhardt Limited A stable pharmaceutical composition of amlodipine and benazepril or salts thereof
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
ES2811347T3 (es) 2015-08-14 2021-03-11 Endocyte Inc Método de formación de imágenes con un compuesto quelante
WO2017068532A1 (en) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
ES3035030T3 (en) 2016-10-07 2025-08-28 Silvergate Pharmaceuticals Inc Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
US10799453B2 (en) 2018-04-11 2020-10-13 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN112955965B (zh) 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
EP4370101A1 (en) 2021-07-15 2024-05-22 Adamed Pharma S.A. A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
IT1203853B (it) 1989-02-23
GR870525B (en) 1987-08-12
CZ289095B6 (cs) 2001-10-17
IE59457B1 (en) 1994-02-23
HU196962B (en) 1989-02-28
PT84611A (en) 1987-05-01
FR2596758A1 (fr) 1987-10-09
DD265142A5 (de) 1989-02-22
GR3000394T3 (en) 1991-06-07
CA1321393C (en) 1993-08-17
IE870869L (en) 1987-10-04
YU58087A (en) 1988-08-31
BE1000130A4 (fr) 1988-04-12
ATE49752T1 (de) 1990-02-15
EP0244944B1 (en) 1990-01-24
NZ219868A (en) 1989-02-24
FI85017B (fi) 1991-11-15
SG59692G (en) 1992-12-04
SK278435B6 (en) 1997-05-07
FR2596758B1 (fr) 1988-12-02
GB2188630B (en) 1990-04-04
ECSP941129A (es) 1994-12-15
PL149532B1 (en) 1990-02-28
JPH037668B2 (enExample) 1991-02-04
MA20938A1 (fr) 1987-12-31
AP50A (en) 1989-09-16
NO172181B (no) 1993-03-08
SE463457B (sv) 1990-11-26
MY101177A (en) 1991-07-31
CS265237B2 (en) 1989-10-13
UA6344A1 (uk) 1994-12-29
PT84611B (pt) 1989-11-30
IT8719977A0 (it) 1987-04-03
DE3761485D1 (de) 1990-03-01
SE8701348D0 (sv) 1987-03-31
SE8701348L (sv) 1987-10-05
NO871408L (no) 1987-10-05
CY1669A (en) 1993-05-14
AU573123B2 (en) 1988-05-26
IL82101A (en) 1991-01-31
GB8707653D0 (en) 1987-05-07
GB2188630A (en) 1987-10-07
SU1498388A3 (ru) 1989-07-30
ES2002599A6 (es) 1988-08-16
US4879303A (en) 1989-11-07
KR870009998A (ko) 1987-11-30
CS353991A3 (en) 1992-04-15
DK171708B1 (da) 1997-04-01
EP0244944A2 (en) 1987-11-11
YU44801B (en) 1991-02-28
NO172181C (no) 1993-06-16
DE3710457A1 (de) 1987-10-08
HUT43821A (en) 1987-12-28
BG60698B2 (en) 1995-12-29
EG18266A (en) 1992-12-30
FI871470L (fi) 1987-10-05
DK170187D0 (da) 1987-04-03
HK76092A (en) 1992-10-09
EP0244944A3 (en) 1988-01-07
ZA872439B (en) 1988-11-30
PH24348A (en) 1990-06-13
FI85017C (fi) 1992-02-25
NO871408D0 (no) 1987-04-03
AU7103087A (en) 1987-10-08
IN168414B (enExample) 1991-03-30
CN87102493A (zh) 1987-10-14
NL8700791A (nl) 1987-11-02
PL264982A1 (en) 1988-05-26
AP8700060A0 (en) 1987-02-01
FI871470A0 (fi) 1987-04-03
AR242562A1 (es) 1993-04-30
KR950006710B1 (ko) 1995-06-21
CS236387A2 (en) 1989-01-12
MX5847A (es) 1993-08-01
CN1023800C (zh) 1994-02-16
LU86812A1 (fr) 1987-08-12
JPS62240660A (ja) 1987-10-21
DK170187A (da) 1987-10-05
ES2012803B3 (es) 1990-04-16
IL82101A0 (en) 1987-10-30

Similar Documents

Publication Publication Date Title
ZA872439B (en) Pharmaceutically acceptable salts
GB2190676B (en) Imidazoquinolinylether derivatives
EP0253500A3 (en) Acylanilide derivatives
GB2198132B (en) 1-piperazinylpyrimidine derivatives
PT86000A (en) Pharmaceutically active compounds
GB8629875D0 (en) Pyridazodiazepine derivatives
EP0277033A3 (en) Vapochromic double-complex salts
GB8701245D0 (en) Pyroglutamide derivatives
GB2198435B (en) Orally active nonaddicting analgesics
EP0247381A3 (en) 5-flurorouracil derivatives
EP0269839B1 (en) 5-acylamino-pyrazole derivatives
GB2198729B (en) Azaspirodecane derivatives
AR245109A1 (es) Un procedimiento para la preparacion de 5-fenil-5h-indeno/1,2-d/ pirimidina.
GB2186575B (en) Abietamide derivatives
GB2189487B (en) Ergolene derivatives
GB8801577D0 (en) Ryfamycin derivatives salts
EP0267024A3 (en) Hydrofluorene derivatives
GR3020329T3 (en) Pharmaceutically active compounds
ZA878046B (en) Pharmaceutically active compounds
IE852063L (en) Cycliciminium salts
GB8717399D0 (en) Alkoxy-substituted 2-dialkylaminobenzene-diazonium salts
GB8620394D0 (en) Complex salts
GB8723520D0 (en) Pharmaceutically useful compounds
GB8823686D0 (en) Pharmaceutically useful compounds
GB8808264D0 (en) Pharmaceutically useful compounds